Nikko Asset Management Americas, Inc. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2022-02-14 06:06 am Sale |
2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Nikko Asset Management Americas, Inc. | 0 0.000% |
-438,199![]() (Position Closed) |
Filing |
2021-02-11 5:27 pm Sale |
2020-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS |
Nikko Asset Management Americas, Inc. | 438,199 9.570% |
-59,267![]() (-11.91%) |
Filing |